Mental Health Client-Level Data (MH-CLD) 2021: Data on Clients Receiving Mental Health Treatment Services Through State Mental Health Agencies annual report presents the total number of clients receiving mental health treatment services in 2021 by demographics, National Outcome Measures (NOMs), and the top five mental health diagnoses for children (ages 0-17) and adults (ages 18 and older) by geographic distribution.

The N-SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the key operational characteristics of substance use and mental health treatment facilities, use of pharmacotherapies, language assistance services, and suicide prevention assistance services.

The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health facilities, use of pharmacotherapies/medications, language assistance provided, and suicide prevention services.

This Advisory, TIP 47, Substance Abuse: Clinical Issues in Intensive Outpatient Treatment, provides an overview of intensive outpatient (IOP) treatment. It discusses typical program goals; outlines key features that improve engagement, retention, and outcomes; and provides additional resources on this critical topic.

This Advisory is based on Technical Assistance Publication (TAP) 21-A, Competencies for Substance Abuse Treatment Clinical Supervisors. It identifies foundational knowledge and concepts essential for supervisory proficiency, roles and skills expected of clinical supervisors, the purpose and context of competencies for supervision in substance use disorder (SUD) treatment programs, and dissemination and implementation of these competencies.

The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).

The report discusses Medicaid coverage of FDA-approved medications for treatment of alcohol and opioid use disorders, limitations on coverage (such as prior authorization requirements), background on federal laws and policies and innovative practices and policies at the state level.

This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.

This pamphlet offers reasons to combine tobacco cessation and substance use disorder treatment, including client testimonials and resources for implementing a tobacco cessation program. It also explains the benefits of offering tobacco cessation programs in substance use disorder treatment settings.